VTGNVistaGen Therapeutics Inc
VTGN
VistaGen Therapeutics Inc18,349
Mkt Cap
$26.31MVolume
1,585.0052W High
$5.1452W Low
$0.6311PE Ratio
-0.41VTGN Fundamentals
Price
$0.6452Prev Close
$0.6638Open
$0.6550D MA
$2.71Beta
2.03Avg. Volume
5.71MEPS (Annual)
-$1.67P/B
0.38Rev/Employee
$8,526.32Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc...
PR Newswire·2d ago
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the...
PR Newswire·2d ago
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN...
PR Newswire·3d ago
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc.
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit...
PR Newswire·4d ago
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire...
PR Newswire·4d ago
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and...
Business Wire·5d ago
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (Vistagen or the Company) (NASDAQ: VTGN) for...
Business Wire·5d ago
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1...
Business Wire·5d ago
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·1mo ago
<
1
2
...
>